Celgene Corp has contracted the UK artificial intelligence company Exscientia Ltd to supply drug discovery services over a period of three years in order to identify new candidate molecules for three programmes in the areas of oncology and autoimmunity.
The alliance is one of several for Exscientia which has also secured collaborations with Roche, GlaxoSmithKline Plc, Sanofi SA and Evotec AG. Celgene, which is soon to be taken over by Bristol-Myers Squibb Co, is also an investor in Exscientia.